ARWR Hits A High, URGN Begins 2018 In Style, ARNA To Report Data In Q1

Shutterstock photo

(RTTNews.com) – The following are some of today’s top gainers in the pharma/biotech sector.

1. Arrowhead Pharmaceuticals Inc. (ARWR)

Gained 24.73% to close Wednesday’s (Jan.3) trading at $4.64. The stock hit a new intraday high of $4.88.


News: No news

Pipeline:

In 2016, Arrowhead had to discontinue development of prior generation drugs, ARC-520, ARC-521, and ARC-AAT, which moved the Company from a clinical-stage company with two Phase 2 candidates and one Phase 1 candidate, to a preclinical-stage company overnight.

ARO-AAT for the treatment of alpha-1 antitrypsin deficiency liver disease; ARO-HBV for the treatment of chronic hepatitis B virus infection, and ARO-APOC3, ARO-ANG3 for the treatment of hypertriglyceridemia are the current compounds in the Company’s pipeline.

Recent events:

— On December 22, 2017, the Company

... read more at: http://www.nasdaq.com/article/arwr-hits-a-high-urgn-begins-2018-in-style-arna-to-report-data-in-q1-20180103-01148

by